secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0000917520-22-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q2 adjusted EPS $0.82 beats prior year; narrows 2022 organic growth guidance to 4.0-5.2%
--------------------------------------------------------------------------------

- Q2 revenue $398M, +2% reported (+4.8% organic); GAAP EPS $0.54 vs $0.41; adjusted EPS $0.82 vs $0.79.
- Full-year 2022 guidance tightened: organic growth 4.0-5.2%; reported revenue $1,557M-$1,575M; adjusted EPS $3.21-$3.29.
- Signed agreement to sell non-core traditional wound care business to Gentell for $28.8M; close expected end of August 2022.
- Codman Specialty Surgical revenue $257.9M (+4.3% organic); Tissue Technologies revenue $140.0M (+5.9% organic).
- Q3 2022 guidance: reported revenue $383M-$391M, organic growth 2.6-4.8%, adjusted EPS $0.78-$0.82.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000037/0000917520-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000037/iart-20220727.htm
  HTML page:      https://secwatch.observer/filing/0000917520-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer